Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones

The efficacy of gemcitabine (GEM), a standard treatment agent for pancreatic cancer, is insufficient because of primary or acquired resistance to this drug. Patients with tumors intrinsically sensitive to GEM gradually acquire resistance and require a shift to second agents, which are associated wit...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Anti-cancer drugs 2015-01, Vol.26 (1), p.90-100
Hauptverfasser:	Yoneyama, Hiroshi, Takizawa-Hashimoto, Asako, Takeuchi, Osamu, Watanabe, Yukiko, Atsuda, Koichiro, Asanuma, Fumiki, Yamada, Yoshinori, Suzuki, Yukio
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Cell Line, Tumor Clone Cells - drug effects Clone Cells - pathology Deoxycytidine - analogs & derivatives Deoxycytidine - pharmacology Drug Resistance, Neoplasm - drug effects Humans Pancreatic Neoplasms - pathology RNA, Messenger - metabolism Tumor Suppressor Proteins - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!